Feb 1st, 2021
HAWTHORNE, NJ, February 1, 2021 – I.W. Tremont has signed a milestone collaborative agreement with East Haven Connecticut based startup 12-15 Molecular Diagnostics Inc. to further their work together in advanced digital nano-sensor design and manufacturing. Tremont is employing cutting edge technologies such as its high-purity diagnostic materials, novel coating techniques, electronic component fabrication and the patented nanocomposite materials developed by its partner 12-15 Molecular Diagnostics. Tremont’s work will be conducted in its recently expanded Hawthorne, New Jersey facility and is expected to increase its employment over the next 12 months.
The sensors are a primary component within the recently announced Verilize rapid COVID screening device. Dr. Saion Sinha the CEO of 12-15 Molecular Devices reports “This exciting technology is proving to be more accurate than current RT-PCR based testing for detection of COVID19 virus in easily obtained non-invasive patient saliva samples”. With reliable results returned in under 20 minutes, the new device offers promise of portability, low cost and adaptability to other viral strains.
“The benefits of this technology extend far beyond COVID19, with the ability to detect many other communicable diseases such as flu, SARS & MRSA” says Jim Averso, Vice President of the second-generation family-owned I.W. Tremont.
Via this relationship 40+ years of Tremont’s high purity porous materials development in the analytical and diagnostics fields have crossed over into digital sensor manufacturing for the advanced technique of DNA hybridization using the latest carbon-based nano materials. “This is truly a powerful partnership between two very capable teams who are focused on solving complex problems” as announced by Salvatore J. Averso, President and founder of I.W. Tremont during a forward-looking technology review.
I.W. Tremont Co., Inc. is a US-based manufacturer of analytical and diagnostic filtration products specializing in glass microfiber and high purity cellulose media with emerging advanced materials capabilities. Unique product lines include specialty materials that are used routinely in life science, medical, environmental, food safety, industrial, transportation, Homeland Security and Defense applications. We manufacture in ISO9001:2015 registered facilities that comply with the FDA’s cGMP. Founded in 1979, the company takes pride in delivering the highest level of customer service and bringing long-term value to the sciences.
12-15 Molecular Diagnostics was formed in 2016, with the development of the advanced technique of Hybridization, which uses carbon-based nanomaterial to process biofluids electronically. Using this technology, the 12-15 team has developed Veralize, a device that enables a 20-minute saliva test for COVID-19 with 95% sensitivity and accuracy. Veralize is currently applying for FDA approval and expects to have a product on the market by the fourth quarter of 2020.